Can you be specific about how NGS-based signatures in metastatic lung cancer can provide actionable roadmaps for targeted therapy?

Can you be specific about how NGS-based signatures in metastatic lung cancer can provide actionable roadmaps for targeted therapy?

Can you be specific about how NGS-based signatures in metastatic lung cancer can provide actionable roadmaps for targeted therapy?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professor James CH Yang, MD, PhD

Professor James CH Yang, MD, PhD

Professor, Graduate Institute of Oncology
National Taiwan University
Director, Department of Oncology
National Taiwan University Hospital
Taipei, Taiwan